ABSTRACT
Objective To investigate the efficacy and safety of cladribine in the treatment of patients with refractory/relapsed acute myeloid leukemia (AML). Methods The data of 8 patients with refractory/relapsed AML treated with regimens containing cladribine at a dose of 5 mg/m2 per day for 5 consecutive days were retrospectively analyzed. The efficacy and adverse reactions were observed during treatment. Results Among the 8 patients, 5 patients achieved complete remission (CR), 1 patient achieved partial response (PR), and 2 patients obtained non remission (NR). The adverse reactions could be tolerated. Conclusion Regimen containing cladribine is an effective treatment procedure for the patients with refractory/relapsed AML, and its adverse reactions can be tolerated, which requires further clinical study.
ABSTRACT
Azacitidine belongs to a novel family of demethylation antitumor drug.Foreign clinical researches have demonstrated that it may be a low toxic and effective choice for elderly patients with acute myeloid leukemia,whose physical conditions are too poor to sustain intensive chemotherapy.This review will summarize recent reports on azacitidine in the treatment of elderly patients with acute myeloid leukemia.